A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
KL Lindsay, C Trepo, T Heintges, ML Shiffman… - Hepatology, 2001 - Elsevier
This international, randomized, active-controlled, parallel-group, double-blind dose-finding
study compared peginterferon alfa-2b (PegIntron™) to interferon alfa-2b for the initial
treatment of compensated chronic hepatitis C. We randomly assigned 1,219 subjects to
receive either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the
once-weekly (QW) peginterferon alfa-2b (0.5, 1.0, or 1.5 μg/kg). Subjects were treated for 48
weeks and then followed for an additional 24 weeks. All 3 peginterferon alfa-2b doses …
study compared peginterferon alfa-2b (PegIntron™) to interferon alfa-2b for the initial
treatment of compensated chronic hepatitis C. We randomly assigned 1,219 subjects to
receive either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the
once-weekly (QW) peginterferon alfa-2b (0.5, 1.0, or 1.5 μg/kg). Subjects were treated for 48
weeks and then followed for an additional 24 weeks. All 3 peginterferon alfa-2b doses …